Adoptive transfer of chimeric FcεRI gene-modified human T cells for cancer immunotherapy

Human Gene Therapy

Volumn 17, Issue 11, 2006, Pages 1134-1143

  Teng, Michele W L ^a   Kershaw, Michael H ^a,b   Jackson, Jacob T ^a   Smyth, Mark J ^a,b   Darcy, Phillip K ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CHIMERIC ANTIBODY; COMPLEMENTARY DNA; CYTOKINE; FC EPSILON RECEPTOR I; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHIMERA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DNA MODIFICATION; EFFECTOR CELL; FC EPSILON RECEPTOR I GENE; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; RETROVIRUS VECTOR; T LYMPHOCYTE; TRANSGENE; TUMOR CELL; VIRAL GENE THERAPY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD28; BASE SEQUENCE; CANCER VACCINES; CELL LINE; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IGE; RECOMBINANT PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES; THYMOMA; TRANSDUCTION, GENETIC;

EID: 33750975088     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.1134     Document Type: Article

References (33)

1. BUBENIK, J. (2004). MHC class I down-regulation: Tumor escape from immune surveillance? [review]. Int. J. Oncol. 25, 487-491.
2. CLEMENCEAU, B., CONGY-JOLIVET, N., GALLOT, G., VIVIEN, R., GASCHET, J., THIBAULT, G., and VIE, H. (2006). Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-spucillc human T lymphocytes. Blood 107, 4669-4677.
3. CORREALE, P., AQUINO, A., GIULIANI, A., PELLEGRINI, M., MICHELI, L., CUSI, M.G., NENCINI, C., PETRIOLI, R., PRETE, S.P., DE VECCHIS, L., TURRIZIANI, M., GIORGI, G., BONMASSAR, E., and FRANCINI, G. (2003). Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-spccific cytotoxic T cells in vivo. Int. J. Cancer 104, 437-445.
4. DUDLEY, M.E., WUNDERLICH, J.R., ROBBINS, P.P., YANG, J.C., HWU, P., SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., SHERRY, R., RESTIFO, N.P., HUBICKI, A.M., ROBINSON, M.R., RAFFELD, M., DURAY, P., SEIPP, C.A., ROGERS-FREEZER, L., MORTON, K.E., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
5. FINNEY, H.M., LAWSON, A.D., BEBBINGTON, C.R., and WEIR, A.N. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797.
6. GOULD, H.J., MACKAY, G.A., KARAGIANNIS, S.N., O'TOOLE, C.M., MARSH, P.J., DANIEL, B.E., CONEY, L.R., ZURAWSKI, V.R., JR., JOSEPH, M., CAPRON, M., GILBERT, M., MURPHY, G.F., and KORNGOLD, R. (1999). Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 29, 3527-3537.
7. GOULD, H.J., SUTTON, B.J., BEAVIL, A.J., BEAVIL, R.L., MCCLOSKEY, N., COKER, H.A., FEAR, D., and SMURTHWAITE, L. (2003). Thebiology of IGEand the basis of allergic disease. Annu. Rev. Immunol. 21, 579-628.
8. εRI) is sufficient for high affinity IgE binding. J. Biol. Chem. 265, 22079-22081.
9. HAYNIES, N.M., TRAPANI, J.A., TENG, M.W., JACKSON, J.T., CERRUTI, L., JANE, S.M., KERSHAW, M.H., SMYTH, M.J., and DARCY, P.K. (2002). Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155-3163.
10. HOATLIN, M.E., KOZAK, S.L., SPIRO, C., and KABAT, D. (1995). Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques. J. Mol. Med. 73, 113-120.
11. HOMBACH, A., WIECZARKOWIECZ, A., MARQUARDT, T., HEUSER, C., USAI, L., POHL, C., SELIGER, B., and ABKEN, H. (2001). Tumor-specific T cell activation by recombinant immunoreceptors: CD3 ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 ζ signaling receptor molecule. J. Immunol. 167, 6123-6131.
12. HULETT, M.D., and HOGARTH, P.M. (1994). Molecular basis of Fc receptor function. Adv. Immunol. 57, 1-127.
13. ISAACS, J.D., WATTS, R.A., HAZLEMAN, B.L., HALE, G., KEOGAN, M.T., COBBOLD, S.P., and WALDMANN, H. (1992). Humunised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748-752.
14. KARAGIANNIS, S.N., WANG, Q., EAST, N., BURKE, P., RIFFARD, S., BRACHER, M.G., THOMPSON, R.G., DURHAM, S.R., SCHWARTZ, L.B., BALKWILL, F.R., and GOULD, H.J. (2003). Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 33, 1030-1040.
15. KAWAKAMI, T., and GALLI, S.J. (2002). Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev. Immunol. 2, 773-786.
16. KERSHAW, M.H., DARCY, P.K., HULETT, M.D., HOGARTH, P.M., TRAPANI, J.A., and SMYTH, M.J. (1996a). Redirected cytotoxic effector function: Requirements tor expression of chimeric single chain high affinity immunoglobulin E receptors. J. Biol. Chem. 271, 21214-21220.
17. ε receptor 1 to redirect cytotoxic T lymphocytes to tumors. J. Leukoc. Biol. 60, 721-72.
18. KERSHAW, M.H., DARCY, P.K., TRAPANI, J.A., MACGREGOR, D., and SMYTH, M.J. (1998). Tumor-specific IgE-niediated inhibition of human cokirecial carcinoma xenograft growth. Oncol. Res. 10, 133-142.
19. KERSHAW, M.H., TENG, M.W., SMYTH, M.J., and DARCY, P.K. (2005). Supernatural T cells: Genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5, 928-940.
20. KESSELS, H.W., WOLKERS, M.C., VAN DEN BOOM, M.D., VAN DER VALK, M.A., and SCHUMACHER, T.N. (2001). Immunotherapy through TCR gene transfer. Nat. Immunol. 2, 957-961.
21. LUBORSKY, J.L., BARUA, A., SHATAVI, S.V., KEBEDE, T., ABRAMOWICZ, J., and ROTMENSCH, J. (2005). Anti-tumor antibodies in ovarian cancer. Am. J. Reprod. Immunol. 54, 55-62.
22. METZGER, H., ALCARAZ, G., HOHMAN, R., KINET, J.P., PRIBLUDA, V., and QUARTO, R. (1986). The receptor with high affinity for immunuglobulin E. Annu. Rev. Immunol. 4, 419-470.
23. + helper T cells induces potent primary and secondary tumor rejection. Blood 106, 2995-3003.
24. NAGY, E., BERCZI, I., and SEHON, A.H. (1991). Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol. Immunother. 34, 63-69.
25. RAVETCH, J.V., and KINET, J.P. (1991). Fc receptors. Annu. Rev. Immunol. 9, 457-492.
26. ROSENBERG, S.A., YANG, J.C., and RESTIFO, N.P. (2004). Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915.
27. ROYAL, R.E., KERSHAW, M.H., REEVES, M.E., WANG, G., DALY, T., TREISMAN, J., LAM, J. and HWU, P. (2002). Increased functional expression ot transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs. Gene Ther. 9, 1085-1092.
28. γ receptor I in cytotoxic T lymphocytes. J. Leukoc. Biol. 55, 514-522.
29. TENG, M.W., KERSHAW, M.H., MOELLER, M., SMYTH, M.J., and DARCY, P.K. (2004). Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum. Gene Ther. 15, 699-708.
30. WATSON, N.F., RAMAGE, J.M., MADJD, Z., SPENDLOVE, I., ELLIS, I.O., SCHOLEFIELD, J.H., and DURRANT, L.G. (2006). Immunosurveillance is active in colorcctal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 118, 6-10.
31. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16168-16173.
32. ZHANG, J.Y., CASIANO, C.A., PENG, X.X., KOZIOL, J.A., CHAN, E.K., and TAN, E.M. (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 12, 136-143.
33. ZHAO, Y. (2005). Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415-4423.